Attend #AMCPNexus 2024 | Las Vegas, Oct. 14-17 Register Now! Close

Letters, Statements & Analysis (2019)

Communicating the importance of managed care pharmacy is a key part of AMCP’s work. Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and the patients we serve.

December

12/16/2019

AMCP submits comments to U.S. House of Representative on 21st Century Cures 2.0

October

10/25/2019

AMCP Joins Stakeholder Letter to the Substance Abuse and Mental Health Services Administration (SAMHSA’s) on Proposed Rule to Update 42 CFR Part 2

August

8/16/2019

AMCP submits comments to the Centers for Medicare and Medicaid Services (CMS) in response to its proposed rule, “Medicare Program; Secure Electronic Prior Authorization for Medicare Part D.” (109.32 KB)

8/12/2019

AMCP Submits Comments to CMS on its Request for Information on Reducing Administrative Burden To Put Patients Over Paperwork (121.89 KB)

July

7/24/2019

Senate Finance Committee releases legislation that includes major overall to Part D, cap in senior’s out-of-pocket costs, limits on price increases in Medicare and Medicaid (213.13 KB)

June

6/3/2019

AMCP responds to Senate HELP Committee’s “Lower Health Care Costs Act” Discussion Draft (245.49 KB)

6/3/2019

AMCP Submits Comments to the Office of the National Coordinator for Health IT (ONC) on its 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program Proposed Rule (324.08 KB)

May

5/31/2019

AMCP comments to the FDA on the Future of Insulin Biosimilars (258.68 KB)

5/18/2019

AMCP joins stakeholder group opposing FDA Update to Biosimilar Naming (187.07 KB)

5/7/2019

AMCP Submitted Comments to the FDA on Updated Draft Guidance on Nonproprietary Naming of Biologics (278.1 KB)

April

4/8/2019

AMCP submits comments to HHS OIG proposed rulemaking on Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions (342.18 KB)

4/3/2019

AMCP sends letter to Governor Hogan asking him to veto Maryland HB 435 which would impose unnecessary restrictions on formulary management (215.87 KB)

March

3/1/2019

AMCP Submits Comments to CMS on Advance Notice of Methodological Changes for Calendar Year (CY) 2020 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2020 Call Letter (1.34 MB)

February

2/28/2019

AMCP Responds to A Request from Senator Alexander on Ways Congress and the Administration can Address the High Cost of Healthcare (390.74 KB)

2/18/2019

AMCP Supports the Reintroduction of H.R. 965, the CREATES ACT (227.73 KB)

AMCP Submits Letter to Ways and Means Committee on Ways to Address Rising Drug Costs (225.93 KB)

AMCP Supports the Reintroduction of S. 340, the CREATES ACT (262.23 KB)

AMCP summary: Food and Drug Administration (FDA) Definition of the Term “Biological Product”

2/12/2019

AMCP submits comments to the Office of Civil Rights (OCR) on its Request for Information on Modifying HIPAA Rules to Improve Coordinated Care (248.56 KB)

2/06/2019

AMCP Summary: Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals (251.01 KB)

2/05/2019

AMCP joins 50 other organizations in support of the reintroduction of the CREATES Act (204.24 KB)

January

1/30/2019

AMCP Summary- Advance Notice of Methodological Changes for Calendar Year (CY) 2020 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2020 Draft Call Letter (317.04 KB)

1/28/2019

On January 28, AMCP submitted comments to HHS and ONC on the HHS Draft Strategy on Reducing Regulatory and Administrative Burden to the Use of Health IT and EHRs (215.58 KB)

1/25/2019

AMCP Submits Comments to CMS on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses proposed rulemaking (290.21 KB)